EDT Clinical trials

Spectral Medical and Vantive Announce Topline Results from Spectral’s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock

Published August 12, 2025 at 08:00 PM

TORONTO, Ontario and DEERFIELD, Ill., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, and Vantive, a vital organ therapy company committed to pursuing novel diagnostic and therapeutic options for organ failure, today announced topline results from the Tigris trial. This Phase 3 follow-on study sponsored by Spectral evaluated the use of Polymyxin B Hemoadsorption (“PMX”) in a randomized clinical trial of adults treated for endotoxic septic shock.

Related Questions

What are the implications of these results for Spectral's partnership with Vantive and any future collaborations? How does the market size for endotoxic septic shock therapy influence the valuation of Spectral Medical? What are the potential competitive responses from other companies developing hemoadsorption or sepsis treatments? What were the primary efficacy endpoints and were they met in the Tigris trial? How does the safety profile of PMX Hemoadsorption compare to existing septic shock therapies? What is the expected timeline for regulatory submission and potential FDA/EMA approval? How will the topline results affect Spectral Medical's projected revenue and cash runway? Will the trial data trigger any milestone payments or earn‑out provisions in existing agreements? How might the results impact the stock's valuation relative to peers in the theranostics and critical care space? What are the next steps in the clinical development program—additional Phase 3 trials, expanded indications, or post‑marketing studies?